摘要
目的分析急性脑梗死患者行大剂量尿激酶溶栓治疗的应用效果及临床价值。方法将医院收治的78例急性脑梗死患者作为研究对象,按照抽签法将其分为治疗组和常规组,各39例。常规组给予小剂量的尿激酶治疗,治疗组给予大剂量的尿激酶治疗。对比两组治疗后的效果。结果治疗后,常规组的治疗总有效率低于治疗组(P <0.05);治疗前,两组的ADL评分相比差异无统计学意义(P> 0.05);治疗后,治疗组的ADL评分较常规组高,差异具有统计学意义(P <0.05);治疗前,两组的NIHSS评分相比差异无统计学意义(P> 0.05);治疗后,治疗组的NIHSS评分低于常规组,差异具有统计学意义(P <0.05)。结论给予急性脑梗死患者大剂量尿激酶溶栓治疗,有效改善了患者的生活功能。
Objective To analyze of the effect and clinical value of high-dose urokinase thrombolytic therapy in patients with acute cerebral infarction. Methods A total of 78 patients with acute cerebral infarction admitted to our hospital as the research object, and they were divided into treatment group and routine group accordding to draw lots, with 39 cases in each group. The routine group was treated with low dose urokinase, and the treatment group was treated with high dose urokinase. The effect of treatment was compared between the two groups. Results After treatment, the total effective rate of the conventional group was lower than that of the treatment group(P<0.05). There was no difference in the ADL score between the two groups before treatment(P>0.05). After treatment, the ADL score of the treatment group was higher than that of the conventional group. The difference was statistically significant(P<0.05). There was no difference in NIHSS score between the two groups before treatment(P>0.05). After treatment, the NIHSS score of the treatment group was lower than that of the conventional group, and the difference was statistically significant(P<0.05). Conclusion High-dose urokinase thrombolytic therapy in patients with acute cerebral infarction can effectively improve the life function of patients.
作者
马文娟
MA Wenjuan(Internal Neurology Department,Jilin People's Hospital,Jilin Jilin 132001,China)
出处
《中国继续医学教育》
2020年第21期138-140,共3页
China Continuing Medical Education
